本帖最后由 老马 于 2012-1-13 21:20 编辑
8 m- H$ F, J8 a
k$ I5 G$ u ?0 y) N0 d爱必妥和阿瓦斯丁的比较
$ a7 L, x) F+ M# a
8 Z$ z+ k) F8 D, a3 ahttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
! |# E! L- H" t2 G' D0 M: X' l. Q
3 y+ N2 j# i7 Q6 y& @# c
! B% ^& A/ w9 h% F! n; O7 V+ ?1 j% i
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/3 [" R& z+ | Q' F& [ k
==================================================& I3 C0 g' _6 o1 n: z4 y1 G
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)& l: [3 j9 `* L, K
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
' P8 w& c J+ h4 `Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. S0 M n) |, Y1 u- v4 O& p
|